Day Zero Diagnostics announced that it received an award of up to $6.2 million in non-dilutive funding from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). The funding from the non-profit partnership dedicated to accelerating early antibacterial R&D is intended to support Day Zero’s diagnostic system designed to help physicians diagnose and treat life-threatening bacterial infections. […]
Cantel Medical announces $150m offering
Cantel Medical (NYSE:CMD) announced today that it intends to offer a private placement worth $150 million in convertible senior notes. Little Falls, N.J.-based Cantel Medical notes intends to grant the initial purchasers of the notes, due in 2025, an option to purchase up to an additional $22.5 million in notes. The unsecured notes will be unsubordinated […]
Tandem Diabetes Care announces $250m offering
Tandem Diabetes Care (NSDQ:TNDM) announced today that it intends to offer a private placement worth $250 million in convertible senior notes. The convertible senior notes, due in 2025, will be senior unsecured obligations of Tandem and are set to accrue interest payable semiannually in arrears, according to a news release. San Diego-based Tandem also intends to […]
AtriCure to raise $100m from public offering
AtriCure (NASDAQ:ATRC) said today that it commenced a public offering to issue and sell roughly $100 million worth of its common stock. The Mason, Ohio–based company — maker of treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management — said it plans to grant the underwriters of the offering a 30-day option to […]
Startup CorVent Medical raises $4.5m for single-use ventilator
CorVent Medical today announced the closing of a $4.5 million seed financing round to support the commercialization of a single-use, critical care ventilator. The financing round is led by European life sciences venture capital firm Sofinnova Partners with participation from Redmile Group, Exor Seeds, Genesis Medtech Group, The Deerfield Foundation, The Pagliuca Family Office and […]
Axonics prices $130m public offering
Axonics Modulation Technologies (NSDQ:AXNX) announced today that it priced a public offering of its common stock with gross proceeds expected to be $130 million. The Irvine, Calif.-based sacral neuromodulation (SNM) device maker is offering 4 million shares of common stock at $32.50 per share, before underwriting discounts and commissions. Underwriters have an additional 30-day option to […]
Vapotherm prices public offering
VapoTherm (NYSE:VAPO) announced today that it priced an underwritten public offering of nearly 3.4 million shares of its common stock. According to a news release, the 3.35 million total shares of the Exeter, N.H.-based respiratory distress treatment developer will be sold at price of $26 per share. In addition, underwriters were granted 30-day option to purchase […]
Second Sight closes $6.8m offering
Second Sight Medical (NSDQ:EYES) announced that it closed an offering of its common stock worth approximately $6.8 million. The maker of visual prosthetic implants for blind individuals priced the offering of 7.5 million common stock shares at $1 per share last week, with Fordham Financial Management’s ThinkEquity division acting as a representative of the underwriters in […]
3M wins federal contracts to further expand U.S. respirator production
3M (NYSE:MMM) announced today that it received two more U.S. Department of Defense contracts to further expand its domestic production of N95 respirator masks. Since January, the Maplewood, Minn.-based company has doubled its global output of respirators to 1.1 billion per year, with 35 million N95 masks produced per month in the U.S. According to a […]
Genetesis completes $9.2m Series B
Cardiac imaging technology developer Genetesis announced today that it completed a Series B financing round worth $9.2 million. Significant investments from TDK Ventures and an undisclosed Fortune 500 company helped to complete the funding, according to a news release. Returning investors CincyTech, Ohio Innovation Fund and Mark Cuban also contributed. Mason, Ohio-based Genetesis develops the […]
Pulmonx raises $66m to commercialize minimally-invasive emphysema treatment
Pulmonx announced today that it raised $66 million in a financing round led by global life science investor Ally Bridge Group. The Redwood City, Calif.-based company also received contributions from new investors Adage Capital Management, HealthQuest Capital, Partner Fund Management and Rock Springs Capital, along with existing investors. Pulmonx secured an additional $17 million in […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 209
- Next Page »
